Analystreport

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) had its "buy" rating re-affirmed by analysts at William Blair.

Pieris Pharmaceuticals, Inc.  (PIRS) 
NASDAQ:AMEX Investor Relations: ir.pieris.com